5 research outputs found
Limits of control for quantum systems: kinematical bounds on the optimization of observables and the question of dynamical realizability
In this paper we investigate the limits of control for mixed-state quantum
systems. The constraint of unitary evolution for non-dissipative quantum
systems imposes kinematical bounds on the optimization of arbitrary
observables. We summarize our previous results on kinematical bounds and show
that these bounds are dynamically realizable for completely controllable
systems. Moreover, we establish improved bounds for certain partially
controllable systems. Finally, the question of dynamical realizability of the
bounds for arbitary partially controllable systems is shown to depend on the
accessible sets of the associated control system on the unitary group U(N) and
the results of a few control computations are discussed briefly.Comment: 5 pages, orginal June 30, 2000, revised September 28, 200
Determination of magnesium in alumina ceramics by atomic absorption spectrometry after separation by cation exchange chromatography
Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry.
BACKGROUND: The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site. METHODS: HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications. RESULTS: We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were older, more frequently male, with more comorbidities and frailer. Their probability of death and ICU admission was higher. However, after adjustment, these differences disappeared. Regarding RASi in-hospital use, those who continued the treatment were younger, with balanced comorbidities but with less severe COVID19. Raw mortality and secondary events were less frequent in RASi. After adjustment, patients receiving RASi still presented significantly better outcomes, with less mortality, ICU admissions, respiratory insufficiency, need for mechanical ventilation or prone, sepsis, SIRS and renal failure (p<0.05 for all). However, we did not find differences regarding the hospital use of RASi and the development of heart failure. CONCLUSION: RASi historic use, at admission, is not related to an adjusted worse prognosis in hospitalized COVID-19 patients, although it points out a high-risk population. In this setting, the in-hospital prescription of RASi is associated with improved survival and fewer short-term complications